Bromodomains: a new target class for drug development

AG Cochran, AR Conery, RJ Sims III - Nature Reviews Drug Discovery, 2019 - nature.com
Less than a decade ago, it was shown that bromodomains, acetyl lysine 'reader'modules
found in proteins with varied functions, were highly tractable small-molecule targets. This is …

Targeting epigenetic modifications in cancer therapy: erasing the roadmap to cancer

HP Mohammad, O Barbash, CL Creasy - Nature medicine, 2019 - nature.com
Epigenetic dysregulation is a common feature of most cancers, often occurring directly
through alteration of epigenetic machinery. Over the last several years, a new generation of …

Iterative design and optimization of initially inactive proteolysis targeting chimeras (PROTACs) identify VZ185 as a potent, fast, and selective von Hippel–Lindau (VHL) …

V Zoppi, SJ Hughes, C Maniaci, A Testa… - Journal of medicinal …, 2018 - ACS Publications
Developing PROTACs to redirect the ubiquitination activity of E3 ligases and potently
degrade a target protein within cells can be a lengthy and unpredictable process, and it …

Bromodomain biology and drug discovery

N Zaware, MM Zhou - Nature structural & molecular biology, 2019 - nature.com
The bromodomain (BrD) is a conserved structural module found in chromatin-and
transcription-associated proteins that acts as the primary reader for acetylated lysine …

Efficient syntheses of diverse, medicinally relevant targets planned by computer and executed in the laboratory

T Klucznik, B Mikulak-Klucznik, MP McCormack… - Chem, 2018 - cell.com
The Chematica program was used to autonomously design synthetic pathways to eight
structurally diverse targets, including seven commercially valuable bioactive substances and …

Degradation of the BAF complex factor BRD9 by heterobifunctional ligands

D Remillard, DL Buckley, J Paulk… - Angewandte Chemie …, 2017 - Wiley Online Library
The bromodomain‐containing protein BRD9, a subunit of the human BAF (SWI/SNF)
nucleosome remodeling complex, has emerged as an attractive therapeutic target in cancer …

Bromodomain inhibitors and cancer therapy: From structures to applications

M Pérez-Salvia, M Esteller - Epigenetics, 2017 - Taylor & Francis
Aberrations in the epigenetic landscape are a hallmark of cancer. Alterations in enzymes
that are “writers,”“erasers,” or “readers” of histone modification marks are common …

[HTML][HTML] Chemical probes and drug leads from advances in synthetic planning and methodology

CJ Gerry, SL Schreiber - Nature Reviews Drug Discovery, 2018 - nature.com
Screening of small-molecule libraries is a productive method for identifying both chemical
probes of disease-related targets and potential starting points for drug discovery. In this …

Bromodomains: Structure, function and pharmacology of inhibition

E Ferri, C Petosa, CE McKenna - Biochemical pharmacology, 2016 - Elsevier
Bromodomains are epigenetic readers of histone acetylation involved in chromatin
remodeling and transcriptional regulation. The human proteome comprises 46 …

Exploiting vulnerabilities of SWI/SNF chromatin remodelling complexes for cancer therapy

M Wanior, A Krämer, S Knapp, AC Joerger - Oncogene, 2021 - nature.com
Multi-subunit ATPase-dependent chromatin remodelling complexes SWI/SNF
(switch/sucrose non-fermentable) are fundamental epigenetic regulators of gene …